Verge Genomics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
61
- Latest Deal Type
-
Later Stage VC
- Investors
-
37
Verge Genomics General Information
Description
Developer of a drug discovery platform designed to accelerate the development of life-saving treatments for neurodegenerative diseases. The company's platform utilizes machine learning to develop therapeutics, specifically for neurological diseases, and can analyze datasets of any size to identify targets and predict effective drugs, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.
Contact Information
Website
www.vergegenomics.comCorporate Office
- 131 Oyster Point Bouleverd
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 131 Oyster Point Bouleverd
- Suite 300
- South San Francisco, CA 94080
- United States
Verge Genomics Timeline
Verge Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 20-Mar-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 08-Sep-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series B1) | 15-Dec-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A1) | 07-Oct-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | 16-Jul-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | 28-Oct-2015 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 18-Aug-2015 | $120K | $120K | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
Verge Genomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B1 | ||||||||
| Series A6 | ||||||||
| Series A5 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 1,698,104 | $0.000100 | 6% | $2.65 | $2.65 | 1x | $2.65 | 3.26% |
| Series A1 | 13,622,216 | $0.000100 | 6% | $3.31 | $3.31 | 1x | $3.31 | 26.12% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Verge Genomics Comparisons
Industry
Financing
Details
Verge Genomics Competitors (59)
One of Verge Genomics’s 59 competitors is Cerecin, a Venture Capital-Backed company based in Denver, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cerecin | Venture Capital-Backed | Denver, CO | ||||
| AltPep | Venture Capital-Backed | Seattle, WA | ||||
| Mitobridge | Formerly VC-backed | Cambridge, MA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| PAQ Therapeutics | Venture Capital-Backed | Cambridge, MA |
Verge Genomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Verge Genomics Patents
Verge Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4118087-A1 | Substituted furo[3,2-d]pyrimidines and uses thereof | Pending | 09-Mar-2020 | ||
| US-20230146395-A1 | Substituted pyrimidines and uses thereof | Pending | 09-Mar-2020 | ||
| AU-2021207804-A1 | Substituted pyrazolo-pyrimidines and uses thereof | Pending | 13-Jan-2020 | ||
| CA-3167339-A1 | Substituted pyrazolo-pyrimidines and uses thereof | Pending | 13-Jan-2020 | ||
| EP-4090426-A1 | Substituted pyrazolo-pyrimidines and uses thereof | Pending | 13-Jan-2020 | C07D487/04 |
Verge Genomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Verge Genomics Investors (37)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BOLD Longevity Growth | Growth/Expansion | Minority | ||
| Ferrer Internacional | Corporation | Minority | ||
| Koru Capital (New York) | Venture Capital | Minority | ||
| Alexion | Corporation | Minority | ||
| AstraZeneca | Corporation | Minority |
Verge Genomics FAQs
-
When was Verge Genomics founded?
Verge Genomics was founded in 2015.
-
Where is Verge Genomics headquartered?
Verge Genomics is headquartered in South San Francisco, CA.
-
What is the size of Verge Genomics?
Verge Genomics has 61 total employees.
-
What industry is Verge Genomics in?
Verge Genomics’s primary industry is Drug Discovery.
-
Is Verge Genomics a private or public company?
Verge Genomics is a Private company.
-
What is Verge Genomics’s current revenue?
The current revenue for Verge Genomics is .
-
How much funding has Verge Genomics raised over time?
Verge Genomics has raised $176M.
-
Who are Verge Genomics’s investors?
BOLD Longevity Growth, Ferrer Internacional, Koru Capital (New York), Alexion, and AstraZeneca are 5 of 37 investors who have invested in Verge Genomics.
-
Who are Verge Genomics’s competitors?
Cerecin, AltPep, Mitobridge, Alzheon, and PAQ Therapeutics are some of the 59 competitors of Verge Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
